Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06355661
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-03-21
Brief Title:
A Study for Assessing the Efficacy and Safety ParActin in Individuals With Upper Respiratory Tract Infections
Sponsor:
Vedic Lifesciences Pvt Ltd
Organization:
Vedic Lifesciences Pvt Ltd
Study Overview
Official Title:
A Double-blind Randomized Placebo-Controlled Comparative Study for Assessing the Efficacy and Safety of ParActin in Individuals With Upper Respiratory Tract Infections URTI
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study is a randomized double-blind placebo-controlled comparative study 176 individuals will be screened and considering a screening failure rate of 15 percent approximately 150 will be randomized in a ratio of 11 to receive either IP or placebo and will be assigned a unique randomization code Each group will have at least 60 completed participants after accounting for a dropoutwithdrawal rate of 20percent The intervention duration for all the study participants is 7 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None